2. Cytoskeleton NF-κB Immunology/Inflammation Apoptosis
  3. Integrin NF-κB Toll-like Receptor (TLR) TNF Receptor
  4. Mumefural

Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment.

For research use only. We do not sell to patients.

Mumefural Chemical Structure

Mumefural Chemical Structure

CAS No. : 222973-44-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Mumefural Related Antibodies

Top Publications Citing Use of Products

View All Integrin Isoform Specific Products:

View All Isoforms
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment[1][2].

IC50 & Target[1]

NF-κB

 

TLR4

 

P-selectin

 

E-selectin

 

TNF-α

 

In Vivo

Mumefural (0.1-10 mg/kg; i.p.; once) shows anti-thrombotic effects in rats[1].
Mumefural (20-80 mg/kg; oral; daily for 42 days) ameliorates cognitive impairment in chronic cerebral hypoperfusion via regulating the septohippocampal cholinergic system and neuroinflammation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SD rats, FeCl3-induced arterial thrombosis model[1]
Dosage: 0.1, 1, or 10 mg/kg
Administration: Intraperitoneal injection, 30 min before 35% FeCl3 treatment
Result: Significantly improved blood flow by inhibiting occlusion and thrombus formation. Prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels.
Animal Model: Male Wistar rats, Chronic cerebral hypoperfusion (CCH) model[2]
Dosage: 20, 40, or 80 mg/kg
Administration: Oral, once a day for 42 days
Result: Significantly improved cognitive impairment. Inhibited cholinergic system dysfunction, attenuated choline acetyltransferase-positive cholinergic neuron loss. Inhibited myelin basic protein degradation and increased the hippocampal expression of synaptic markers and cognition-related proteins. Reduced neuroinflammation, inhibited gliosis, and attenuated the activation of P2X7 receptor, TLR4/MyD88, NLRP3, and NF-κB.
Animal Model: SD rats[1]
Dosage: 2 or 10 mg/kg
Administration: IV or PO (Pharmacokinetic Analysis)
Result: Plasma pharmacokinetic parameters of Mumefural in SD rats[1]
T1/2 (h) Tmax (h) Cmax (ng/mL) AUC0-t (ng⋅h/mL) F (%)
IV (2 mg/kg) 0.14±0.05 0.08±0 1894.54±580.66 564.73±178.35 -
PO (2 mg/kg) 0.69±0.69 0.31±0.13 1731.61±290.64 1043.28±202.37 36.95±7.17

AUC(0–t): area under the curve from the time of dosing to infinity; Cmax: maximum concentration; F: bioavailability; T1/2: terminal half-life; Tmax: time of the maximum concentration; SD: standard deviation; F was calculated using the following formula
Molecular Weight

300.22

Formula

C12H12O9
CAS No.
SMILES

O=C(CC(C(O)=O)(O)CC(O)=O)OCC1=CC=C(C=O)O1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Mumefural Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mumefural222973-44-6IntegrinNF-κBToll-like Receptor (TLR)TNF ReceptorNuclear factor-κBNuclear factor-kappaBTumor Necrosis Factor ReceptorTNFRanti-thromboticSD ratsP-selectinE-selectinTLR4TNF-αIL-6Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mumefural
Cat. No.:
HY-N8903
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.